FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Federal Register

Orthopedic Surgical Instruments Put Into Class 2

Federal Register notice: FDA classifies orthopedic surgical instrumentation designed for osteochondral implants with press-fit fixation into Class 2 (...

Federal Register

Draft Guide on Homeopathic Drug Products

Federal Register notice: FDA makes available a revised draft guidance entitled Drug Products Labeled as Homeopathic.

Federal Register

Allergan NDA Lo Minastrin FE Withdrawn

Federal Register notice: FDA withdraws the NDA approval of Allergan Pharmaceuticals Lo Minastrin FE because it is no longer marketed.

Federal Register

Internal Therapeutic Massagers Put Into Class 2

Federal Register notice: FDA classifies internal therapeutic massagers into Class 2 (special controls).

Medical Devices

FDAs Growing Concern on Device Sterilization

FDA grows concerned over recent closures of certain large-scale sterilization facilities that use ethylene oxide to sterilize medical devices prior to...

Medical Devices

Impella Heart Pump Study Confirms Survival Data

Abiomed says that a post-approval study confirmed survival data in its pre-approval study for the Impella RP heart pump.

Federal Register

Five Class 2 Devices Exempt from 510(k)

Federal Register notice: FDA announces its decision to exempt a list of Class 2 devices from premarket notification requirements.

Human Drugs

Melintas Baxdela Expanded Approval for Pneumonia

FDA approves a Melinta Therapeutics supplemental NDA for Baxdela (delafloxacin) for treating adult patients with community-acquired bacterial pneumoni...

Human Drugs

NuCana Phase 3 Bilary Tract Cancer Study

FDA authorizes NuCana to begin a Phase 3 study (nutide:121) of the investigational drug Acelarin in combination with cisplatin for patients with previ...

Federal Register

Draft Guide on Postmarketing Studies/Trials

Federal Register notice: FDA makes available a draft guidance entitled Postmarketing Studies and Clinical Trials Implementation of Section 505(o)(3) ...